Loading...

Akcea Therapeutics

DB:1KA
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
1KA
DB
$2B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The last earnings update was 14 days ago. More info.


Add to Portfolio Compare Print
  • Akcea Therapeutics has significant price volatility in the past 3 months.
1KA Share Price and Events
7 Day Returns
-3%
DB:1KA
3.3%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-5.6%
DB:1KA
-8.4%
DE Biotechs
-10.8%
DE Market
1KA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Akcea Therapeutics (1KA) -3% -23.9% -21.1% -5.6% - -
DE Biotechs 3.3% 4.5% 1.2% -8.4% 55.3% 9.8%
DE Market -0.6% -3.3% 2.3% -10.8% 8% 8%
1 Year Return vs Industry and Market
  • 1KA outperformed the Biotechs industry which returned -8.4% over the past year.
  • 1KA outperformed the Market in Germany which returned -10.8% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Akcea Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Akcea Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €18.75.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Akcea Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Akcea Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:1KA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-2.02
NasdaqGS:AKCA Share Price ** NasdaqGS (2019-05-23) in USD $21.37
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.59x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 20.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Akcea Therapeutics.

DB:1KA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:AKCA Share Price ÷ EPS (both in USD)

= 21.37 ÷ -2.02

-10.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akcea Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Akcea Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Akcea Therapeutics's expected growth come at a high price?
Raw Data
DB:1KA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -10.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
32.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.27x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.51x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Akcea Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Akcea Therapeutics's assets?
Raw Data
DB:1KA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.20
NasdaqGS:AKCA Share Price * NasdaqGS (2019-05-23) in USD $21.37
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.36x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.78x
DB:1KA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:AKCA Share Price ÷ Book Value per Share (both in USD)

= 21.37 ÷ 4.20

5.09x

* Primary Listing of Akcea Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Akcea Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Akcea Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Akcea Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Akcea Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Akcea Therapeutics expected to grow at an attractive rate?
  • Akcea Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Akcea Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Akcea Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:1KA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:1KA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 32.6%
DB:1KA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 27.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 52.7%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 32.9%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.2%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:1KA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:1KA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,060 128 171 1
2022-12-31 600 -8 -37 2
2021-12-31 316 -46 -185 3
2020-12-31 459 -47 -164 4
2019-12-31 249 -106 -147 5
DB:1KA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 212 -108 -177
2018-12-31 65 -203 -234
2018-09-30 88 -159 -184
2018-06-30 79 -114 -93
2018-03-31 54 -79 -59
2017-12-31 43 -36 -93
2017-09-30 22 -63 -90
2017-06-30 12 -47 -92
2017-03-31 6 -28 -131
2016-12-31 -55 -83
2016-09-30 -42 -75

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Akcea Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Akcea Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:1KA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Akcea Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1KA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.62 1.62 1.62 1.00
2022-12-31 -0.38 -0.36 -0.39 2.00
2021-12-31 -1.89 -1.47 -2.30 3.00
2020-12-31 -1.08 1.57 -3.15 5.00
2019-12-31 -1.24 0.16 -1.83 5.00
DB:1KA Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -2.02
2018-12-31 -2.87
2018-09-30 -2.43
2018-06-30 -1.38
2018-03-31 -0.88
2017-12-31 -3.08
2017-09-30 -1.35
2017-06-30 -1.39
2017-03-31
2016-12-31
2016-09-30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Akcea Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Akcea Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Akcea Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Akcea Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Akcea Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Akcea Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Akcea Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Akcea Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Akcea Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Akcea Therapeutics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:1KA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 211.58 -176.80 177.10
2018-12-31 64.87 -233.61 151.96
2018-09-30 88.17 -184.40 122.93
2018-06-30 78.83 -92.87 87.14
2018-03-31 54.42 -58.95 51.77
2017-12-31 43.40 -93.17 36.98
2017-09-30 21.71 -90.11 25.11
2017-06-30 11.81 -92.34 19.63
2017-03-31 6.09 -131.11 15.48
2016-12-31 -83.22 15.05
2016-09-30 -75.45 15.16 20.83
2016-03-31 -68.40 13.47 43.23
2015-12-31 -61.42 10.55
2014-12-31 -30.02 1.00 29.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Akcea Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Akcea Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Akcea Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Akcea Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Akcea Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Akcea Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Akcea Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Akcea Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Akcea Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Akcea Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 21.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Akcea Therapeutics Company Filings, last reported 1 month ago.

DB:1KA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 388.86 16.32 321.79
2018-12-31 276.72 0.00 252.61
2018-09-30 281.41 0.00 320.32
2018-06-30 290.40 0.00 381.85
2018-03-31 146.30 0.00 244.94
2017-12-31 167.83 0.00 260.13
2017-09-30 197.84 0.00 286.13
2017-06-30 -82.98 107.51 118.67
2017-03-31 -74.94 91.54 124.52
2016-12-31 -17.75 0.00 7.86
2016-09-30 13.62 0.00 59.46
2016-03-31 42.56 0.00 63.26
2015-12-31 55.27 0.00 64.31
2014-12-31 1.58 0.00
  • Akcea Therapeutics's level of debt (4.2%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Akcea Therapeutics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Akcea Therapeutics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Akcea Therapeutics has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 55.1% each year.
X
Financial health checks
We assess Akcea Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Akcea Therapeutics has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Akcea Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Akcea Therapeutics dividends.
If you bought €2,000 of Akcea Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Akcea Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Akcea Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:1KA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:1KA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Akcea Therapeutics has not reported any payouts.
  • Unable to verify if Akcea Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Akcea Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Akcea Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Akcea Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Akcea Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Akcea Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Akcea Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paula Soteropoulos
COMPENSATION $5,209,531
AGE 50
TENURE AS CEO 4.3 years
CEO Bio

Ms. Paula Soteropoulos has been the Chief Executive Officer and Director of Akcea Therapeutics, Inc. since January 2015 and served as President since January 2015 until April 17, 2018. Prior to joining Akcea, Ms. Soteropoulos was a member of the executive leadership team of Moderna Therapeutics as the Cardiometabolic Business Unit General Manager and Senior Vice President of Strategic Alliances from July 2013 to December 2014, a global strategic and operating management executive with over 25 years of success at building high-performance global teams, leading complex development programs from early stage through approval and commercializing global products. Prior to Moderna, Ms. Soteropoulos served as the Vice President and General Manager of Genzyme’s Global Cardiovascular business. She was responsible for the development and commercialization of multiple therapeutics across Renal, Transplant & Oncology, Rare Disease and Cardiovascular. During her tenure at Genzyme, she was instrumental in advancing new compounds from discovery through clinical development and commercialization with significant roles driving product strategy, portfolio, program and alliance management, sales and marketing and business development. Additionally, Ms. Soteropoulos led strategic manufacturing capacity planning, supply chain development and manufacturing process development. Prior to Genzyme, she was a Bioprocess Engineering Consultant for various biopharmaceutical companies. She serves as Director at JFYNet. She has been a Director of uniQure N.V. since July 22, 2013. She serves as a Member of Advisory Board at the Tufts University Chemical and Biological Engineering Department. She is a Member of the Healthcare Business Women’s Association and serves as a Mentor. She was a honoree of Mass High Tech’s Women to Watch. She served as a Member of Supervisory Board at uniQure N.V. since July 22, 2013 until June 15, 2016. Ms. Soteropoulos earned her B.S. and M.S. in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia.

CEO Compensation
  • Paula's compensation has increased whilst company is loss making.
  • Paula's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Akcea Therapeutics management team in years:

1.4
Average Tenure
50
Average Age
  • The average tenure for the Akcea Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Paula Soteropoulos

TITLE
CEO & Director
COMPENSATION
$5M
AGE
50
TENURE
4.3 yrs

Sarah Boyce

TITLE
President & Director
COMPENSATION
$19M
AGE
46
TENURE
1.1 yrs

Jeffrey Goldberg

TITLE
Chief Operating Officer
COMPENSATION
$8M
AGE
45
TENURE
4.3 yrs

Michael MacLean

TITLE
Chief Financial Officer
COMPENSATION
$5M
AGE
52
TENURE
1.8 yrs

Kathleen Gallagher

TITLE
Vice President of Communications & Investor Relations

Joshua Patterson

TITLE
VP of Legal & Corporate Secretary

Daniel Moynihan

TITLE
Chief Compliance Officer
TENURE
0.3 yrs

Maura Bullock

TITLE
Vice President of Human Resources
TENURE
0.8 yrs

Molly Harper

TITLE
Senior VP & Global Franchise GM
TENURE
0.3 yrs

Louis St. O'Dea

TITLE
Chief Medical Officer
COMPENSATION
$2M
AGE
67
TENURE
3.3 yrs
Board of Directors Tenure

Average tenure and age of the Akcea Therapeutics board of directors in years:

2.2
Average Tenure
63
Average Age
  • The average tenure for the Akcea Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Gabrieli

TITLE
Chairman
COMPENSATION
$564K
AGE
58
TENURE
2.2 yrs

Paula Soteropoulos

TITLE
CEO & Director
COMPENSATION
$5M
AGE
50
TENURE
4.3 yrs

Sarah Boyce

TITLE
President & Director
COMPENSATION
$19M
AGE
46
TENURE
1.1 yrs

B. Parshall

TITLE
Director
COMPENSATION
$2M
AGE
64
TENURE
4.3 yrs

Sandy Smith

TITLE
Independent Director
COMPENSATION
$593K
AGE
71
TENURE
2.2 yrs

Ed Fitzgerald

TITLE
Director
COMPENSATION
$591K
AGE
63
TENURE
2 yrs

John Kastelein

TITLE
Member of Cardio Metabolic Advisory Board
AGE
64

Joe Witztum

TITLE
Member of Cardio Metabolic Advisory Board

Sam Tsimikas

TITLE
Member of Cardio Metabolic Advisory Board

Rosanne Crooke

TITLE
Member of Cardio Metabolic Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Akcea Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Akcea Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.

Details
Name: Akcea Therapeutics, Inc.
1KA
Exchange: DB
Founded: 2014
$1,775,331,779
92,770,397
Website: http://www.akceatx.com
Address: Akcea Therapeutics, Inc.
22 Boston Wharf Road,
9th Floor,
Boston,
Massachusetts, 02210,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS AKCA Common Stock Nasdaq Global Select US USD 14. Jul 2017
DB 1KA Common Stock Deutsche Boerse AG DE EUR 14. Jul 2017
Number of employees
Current staff
Staff numbers
248
Akcea Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/23 22:37
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/10
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.